MeiraGTx (MGTX) said Monday that AAV2-hAQP1 received regenerative medicine advanced therapy designation from the US Food and Drug Administration.
AAV2-hAQP1 is being developed for the treatment of grade 2/3 radiation-induced xerostomia, a common side effect of head and neck cancer radiotherapy that causes dry mouth, according to the company.
The company's drug candidate also received orphan drug designation from the FDA previously and the RMAT designation will allow for frequent regulatory interactions with the agency, MeiraGTx said.
Shares of the company were up 6.1% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。